Cargando…

Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area

Background: Over the past decade, three new drugs have been approved for the treatment of hereditary amyloid transthyretin (ATTRv) polyneuropathy. The aim of this work was to analyze whether current therapies prolong survival for patients affected by ATTRv amyloidosis. Methods: The study was conduct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russo, Massimo, Gentile, Luca, Di Stefano, Vincenzo, Di Bella, Gianluca, Minutoli, Fabio, Toscano, Antonio, Brighina, Filippo, Vita, Giuseppe, Mazzeo, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146901/ https://www.ncbi.nlm.nih.gov/pubmed/33925301 http://dx.doi.org/10.3390/brainsci11050545

Ejemplares similares

Machine Learning for Early Diagnosis of ATTRv Amyloidosis in Non-Endemic Areas: A Multicenter Study from Italy
por: Di Stefano, Vincenzo, et al.
Publicado: (2023)

Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects
por: Russo, Massimo, et al.
Publicado: (2020)

TTR-FAP: a single-center experience in Sicily, an Italian endemic area
por: Mazzeo, Anna, et al.
Publicado: (2015)

Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area
por: Mazzeo, Anna, et al.
Publicado: (2015)

Is 99mTc-diphosphonate uptake the earliest sign of cardiac amyloidosis development in asymptomatic Glu89Gln transthyretin gene mutation carriers?
por: Minutoli, Fabio, et al.
Publicado: (2015)

Quantitative comparison between amyloid deposition detected by 99mTc-diphosphonate imaging and myocardial deformation evaluated by strain echocardiography in transthyretin related cardiac amyloidosis
por: Di Bella, Gianluca, et al.
Publicado: (2015)

Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy
por: Magliano, Lorenza, et al.
Publicado: (2021)

Patisiran Enhances Muscle Mass after Nine Months of Treatment in ATTRv Amyloidosis: A Study with Bioelectrical Impedance Analysis and Handgrip Strength
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

Usefulness of combining electrocardiogram and echocardiography findings and brain natriuretic peptide in early detection of cardiac amyloidosis in subjects with transthyretin gene mutation
por: Di Bella, Gianluca, et al.
Publicado: (2015)

Current Evidence Supporting the Role of Immune Response in ATTRv Amyloidosis
por: Plantone, Domenico, et al.
Publicado: (2023)

Early Impairment of Right Ventricular Morphology and Function in Transthyretin-Related Cardiac Amyloidosis
por: Licordari, Roberto, et al.
Publicado: (2021)

ATTRv in Lazio-Italy: A High-Prevalence Region in a Non-Endemic Country
por: Luigetti, Marco, et al.
Publicado: (2021)

The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis
por: Vera-Llonch, Montserrat, et al.
Publicado: (2021)

Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis
por: Matsushita, Hiroaki, et al.
Publicado: (2022)

Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy
por: Dardiotis, Efthimios, et al.
Publicado: (2023)

Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis
por: Vita, Gian Luca, et al.
Publicado: (2020)

Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features
por: Pozsonyi, Zoltán, et al.
Publicado: (2021)

Ocular findings in patients with acquired ATTRv amyloidosis following domino liver transplantation
por: Kitahara, Junya, et al.
Publicado: (2023)

Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy
por: Gentile, Luca, et al.
Publicado: (2021)

Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca
por: Cisneros-Barroso, E., et al.
Publicado: (2023)

The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data
por: Reddy, Sheila R., et al.
Publicado: (2020)

Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen
por: Coelho, Teresa, et al.
Publicado: (2022)

Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS
por: Gentile, Luca, et al.
Publicado: (2021)

A narrative review and expert recommendations on the assessment of the clinical manifestations, follow-up, and management of post-OLT patients with ATTRv amyloidosis
por: Casasnovas, Carlos, et al.
Publicado: (2023)

Prevalence estimation of ATTRv in China based on genetic databases
por: Yongsheng, Zheng, et al.
Publicado: (2023)

Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
por: Gentile, Luca, et al.
Publicado: (2021)

Trajectories of Kidney Function in Patients with ATTRv Treated with Gene Silencers
por: Luigetti, Marco, et al.
Publicado: (2022)

Practice of Hereditary ATTR Amyloidosis in Non-endemic Areas of Japan
por: Matsushima, Masaaki, et al.
Publicado: (2022)

Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years
por: Gentile, L., et al.
Publicado: (2020)

Cutaneous amyloid is a biomarker in early ATTRv neuropathy and progresses across disease stages
por: Freeman, Roy, et al.
Publicado: (2022)

Case Report: Hereditary transthyretin (ATTRv) amyloidosis: The p.G103R mutation of the transthyretin gene in a Han Chinese family is associated with vitreous hemorrhage
por: Shen, Junhui, et al.
Publicado: (2022)

Quantitative Sensory Testing in Late-Onset ATTRv Presymptomatic Subjects: A Single Center Experience
por: Tozza, Stefano, et al.
Publicado: (2022)

Deterioration after Liver Transplantation and Transthyretin Stabilizer Administration in a Patient with ATTRv Amyloidosis with a Leu58Arg (p.Leu78Arg) TTR Variant
por: Hikishima, Sadao, et al.
Publicado: (2022)

Motor Conduction Studies and Handgrip in Hereditary TTR Amyloidosis: Simple Tools to Evaluate the Upper Limbs
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

A novel TTR mutation (p.Ala65Val) underlying late-onset hereditary transthyretin (ATTRv) amyloidosis with mixed cardiac and neuropathic phenotype: a case report
por: Thimm, Andreas, et al.
Publicado: (2022)

Monitoring safety and effectiveness of Tafamidis in transthyretin amyloidosis in Italy: a 3-year longitudinal multicenter study in a non-endemic area
por: Cortese, Andrea, et al.
Publicado: (2015)

Ocular Morpho-Functional Evaluation in ATTRv Pre-Symptomatic Carriers: A Case Series
por: Maceroni, Martina, et al.
Publicado: (2023)

Study of the parent-of-origin effect in monogenic diseases with variable age of onset. Application on ATTRv
por: Alarcon, Flora, et al.
Publicado: (2023)

Parenteral nutrition improves nutritional status, autonomic symptoms and QoL in patients with TTR-FAP
por: Russo, Massimo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v3e5hgk9gqpr1jsigb5i4a9787